The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of the vaccine Arexvy (recombinant, adjuvanted), for use against lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults aged 60 and older.

Arexvy was evaluated through the EMA's accelerated assessment mechanism ...